Why the study?
Does preoperative fibrinogen concentration predict perioperative blood loss and composite morbidity in patients receiving dual antiplatelet therapy in proximity to OPCAB?
Does preoperative fibrinogen concentration predict perioperative blood loss and composite morbidity in patients receiving dual antiplatelet therapy in proximity to OPCAB?
In patients receiving dual antiplatelet therapy shortly before OPCAB, elevated preoperative fibrinogen is an independent predictor of postoperative ischemic morbidity, whereas low fibrinogen does not independently predict increased bleeding.
Elevated fibrinogen may flag higher ischemic morbidity risk in DAPT patients before OPCAB; leaves open utility for risk stratification or management changes.
BACKGROUND: Preoperative fibrinogen concentration is associated with increased blood loss at the lower end, and with hypercoagulability-related ischemic event at the higher end in cardiac patients. We evaluated the influence of preoperative fibrinogen concentration on blood loss and outcome in patients who received clopidogrel in proximity to off-pump coronary artery bypass surgery (OPCAB). METHODS AND RESULTS: Medical records of 538 patients who received clopidogrel within 5 days of OPCAB (April 2007 to March 2012) were retrospectively reviewed. Perioperative bleeding and composite of morbidity endpoints including myocardial infarction were compared in relation to the tertile distribution of the fibrinogen concentration. The amount of blood loss was significantly larger in the first tertile, whereas the incidence of composite of morbidity endpoints was significantly higher in the third tertile. In multivariate analysis for risk factors of perioperative blood loss, body mass index and duration of surgery were identified as independent risk factors but not the fibrinogen level. And hypertension and preoperative fibrinogen level were identified as independent risk factors about composite of morbidity. The third tertile was associated with a 2-fold increased risk of developing composite of morbidity endpoints. CONCLUSIONS: In patients who received dual antiplatelet therapy in proximity to OPCAB, increased preoperative fibrinogen concentration could serve as a valuable predictor for composite of morbidity endpoints, whereas low fibrinogen concentration was not found to be a risk factor of bleeding.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: